Page last updated: 2024-11-03

riluzole and Atrophy

riluzole has been researched along with Atrophy in 4 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
" In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging."5.10The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. ( Barkhof, F; Bergers, E; Kalkers, NF; Polman, CH; van Schijndel, R, 2002)
"Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients."1.43Longitudinal associations between brain structural changes and fatigue in early MS. ( Azevedo, C; Maghzi, AH; Nourbakhsh, B; Nunan-Saah, J; Pelletier, D; Spain, R; Waubant, E, 2016)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nourbakhsh, B3
Azevedo, C2
Nunan-Saah, J1
Maghzi, AH2
Spain, R2
Pelletier, D3
Waubant, E3
Kuhle, J1
Grant, D1
Morant, S1
Barro, C1
Yaldizli, Ö1
Giovannoni, G1
Gnanapavan, S1
Kalkers, NF1
Barkhof, F1
Bergers, E1
van Schijndel, R1
Polman, CH1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis[NCT00501943]Phase 243 participants (Actual)Interventional2006-07-31Completed
Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.[NCT04593082]116 participants (Anticipated)Observational2021-06-03Recruiting
OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661]Phase 230 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in MS Functional Composite (MSFC)

Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test. (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24

Interventionpercent change per year (Mean)
Riluzole0.041
Placebo0.052

Changes in Normalized Grey Matter Volume

The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12 and Month-24

Interventionpercent change per year (Mean)
Riluzole-14.369
Placebo-18.444

Changes in Normalized White Matter Volumes (nWMV)

The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24

Interventionpercent change per year (Mean)
Riluzole-1.75
Placebo-9.69

Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)

Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24

Interventionpercent change per year (Mean)
Riluzole-4.670
Placebo-1.839

Changes in Symbol Digit Modality Test (SDMT)

Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24

Interventionpercent change per year (Mean)
Riluzole0.342
Placebo0.417

MRI Parameter- Percent Brain Volume Change for 2 Years

Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X) (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24

Interventionpercent change per year (Mean)
Riluzole-0.862
Placebo-0.49

Trials

3 trials available for riluzole and Atrophy

ArticleYear
Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    Journal of the neurological sciences, 2016, Jul-15, Volume: 366

    Topics: Adjuvants, Immunologic; Adult; Atrophy; Brain; Cross-Sectional Studies; Disability Evaluation; Disea

2016
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology, 2017, Feb-28, Volume: 88, Issue:9

    Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio

2017
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology, 2017, Feb-28, Volume: 88, Issue:9

    Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio

2017
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology, 2017, Feb-28, Volume: 88, Issue:9

    Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio

2017
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology, 2017, Feb-28, Volume: 88, Issue:9

    Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio

2017
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2002, Volume: 8, Issue:6

    Topics: Adult; Aged; Atrophy; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclero

2002

Other Studies

1 other study available for riluzole and Atrophy

ArticleYear
Longitudinal associations between brain structural changes and fatigue in early MS.
    Multiple sclerosis and related disorders, 2016, Volume: 5

    Topics: Adult; Atrophy; Brain; Fatigue; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Ma

2016